Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Focus on habits that remain sustainable indefinitely rather than extreme measures requiring medication support
According to the Summary of Product Characteristics (SmPC), these include: Nausea (very common, affecting more than 1 in 10 people) Diarrhoea (very common) Decreased appetite (very common) Vomiting (common, affecting up to 1 in 10 people) Constipation (common) Abdominal pain (common) Dyspepsia (common) Cholelithiasis (common) Headache (common) These gastrointestinal effects typically occur during the initial weeks of treatment or following dose escalation, and often diminish over time as the body adjusts to the medication
What are Mounjaro tirzepatide Injections
[1] [2] Pancreatitis and gallbladder disease are recognised class-safety signals with GLP-1-based agents, and the evidence base for retatrutide in this regard is still emerging
US$ 29.01
US$ 23.92
US$ 27.26
US$ 29.37
